PMC:7205724 / 1463-1669
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
51 | 47-50 | Gene | denotes | IL6 | Gene:3569 |
52 | 104-107 | Gene | denotes | IL6 | Gene:3569 |
61 | 85-93 | Species | denotes | patients | Tax:9606 |
62 | 148-157 | Species | denotes | SARS-CoV2 | Tax:2697049 |
64 | 4-15 | Chemical | denotes | Tocilizumab | MESH:C502936 |
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T5 | 30-38 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T6 | 158-162 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T18 | 148-152 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T5 | 17-18 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T6 | 158-162 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T3 | 158-162 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T18 | 148-157 | Species | denotes | SARS-CoV2 | NCBItxid:2697049 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T19 | 4-115 | Sentence | denotes | Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
64 | 4-15 | Chemical | denotes | Tocilizumab | MESH:C502936 |
51 | 47-50 | Gene | denotes | IL6 | Gene:3569 |
61 | 85-93 | Species | denotes | patients | Tax:9606 |
52 | 104-107 | Gene | denotes | IL6 | Gene:3569 |
62 | 148-157 | Species | denotes | SARS-CoV2 | Tax:2697049 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T177 | 47-50 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
T221 | 104-107 | Protein | denotes | IL6 | https://www.uniprot.org/uniprot/Q9XT80|https://www.uniprot.org/uniprot/Q9UCU4|https://www.uniprot.org/uniprot/Q9UCU3|https://www.uniprot.org/uniprot/Q9UCU2|https://www.uniprot.org/uniprot/Q9MZR1|https://www.uniprot.org/uniprot/Q9MYZ7|https://www.uniprot.org/uniprot/Q95KN6|https://www.uniprot.org/uniprot/Q95181|https://www.uniprot.org/uniprot/Q90YI0|https://www.uniprot.org/uniprot/Q8MKH0|https://www.uniprot.org/uniprot/Q8BN26|https://www.uniprot.org/uniprot/Q865X6|https://www.uniprot.org/uniprot/Q865W7|https://www.uniprot.org/uniprot/Q6V919|https://www.uniprot.org/uniprot/Q6L6X6|https://www.uniprot.org/uniprot/Q5I6E3|https://www.uniprot.org/uniprot/Q3UCQ0|https://www.uniprot.org/uniprot/Q2MH06|https://www.uniprot.org/uniprot/Q28819|https://www.uniprot.org/uniprot/Q28747|https://www.uniprot.org/uniprot/Q28319|https://www.uniprot.org/uniprot/Q25BC2|https://www.uniprot.org/uniprot/Q0PW36|https://www.uniprot.org/uniprot/Q0GGL7|https://www.uniprot.org/uniprot/Q08DT2|https://www.uniprot.org/uniprot/P79341|https://www.uniprot.org/uniprot/P51494|https://www.uniprot.org/uniprot/P46650|https://www.uniprot.org/uniprot/P41693|https://www.uniprot.org/uniprot/P41683|https://www.uniprot.org/uniprot/P41323|https://www.uniprot.org/uniprot/P29455|https://www.uniprot.org/uniprot/P26893|https://www.uniprot.org/uniprot/P26892|https://www.uniprot.org/uniprot/P20607|https://www.uniprot.org/uniprot/P08505|https://www.uniprot.org/uniprot/P05231|https://www.uniprot.org/uniprot/O46568|https://www.uniprot.org/uniprot/O35736|https://www.uniprot.org/uniprot/O19007|https://www.uniprot.org/uniprot/B6CKP4|https://www.uniprot.org/uniprot/A9QWQ9|https://www.uniprot.org/uniprot/A3FBE9|https://www.uniprot.org/uniprot/A0S0B0 |
LitCovid-sample-Enju
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T222 | 4-15 | NNP | denotes | Tocilizumab |
T223 | 15-16 | -COMMA- | denotes | , |
T224 | 17-18 | DT | denotes | a |
T225 | 19-29 | JJ | denotes | monoclonal |
T226 | 30-38 | NN | denotes | antibody |
T227 | 39-46 | IN | denotes | against |
T228 | 47-50 | NN | denotes | IL6 |
T229 | 50-51 | -COMMA- | denotes | , |
T230 | 52-57 | MD | denotes | could |
T231 | 58-64 | VB | denotes | confer |
T232 | 65-73 | JJ | denotes | clinical |
T233 | 74-81 | NN | denotes | benefit |
T234 | 82-84 | IN | denotes | in |
T235 | 85-93 | NNS | denotes | patients |
T236 | 94-98 | IN | denotes | with |
T237 | 99-103 | JJ | denotes | high |
T238 | 104-107 | NN | denotes | IL6 |
T239 | 108-114 | NNS | denotes | levels |
T240 | 116-125 | JJ | denotes | Essential |
T241 | 126-134 | NNS | denotes | elements |
T242 | 135-139 | IN | denotes | that |
T243 | 140-147 | NN | denotes | process |
T244 | 148-157 | NN | denotes | SARS-CoV2 |
T245 | 158-162 | NN | denotes | cell |
T246 | 163-168 | NN | denotes | entry |
T247 | 169-172 | CC | denotes | and |
T248 | 173-181 | JJ | denotes | specific |
T249 | 182-197 | NNS | denotes | characteristics |
T250 | 198-202 | WDT | denotes | that |
R213 | T222 | T223 | arg1Of | Tocilizumab,"," |
R214 | T226 | T223 | arg2Of | antibody,"," |
R215 | T226 | T224 | arg1Of | antibody,a |
R216 | T226 | T225 | arg1Of | antibody,monoclonal |
R217 | T226 | T227 | arg1Of | antibody,against |
R218 | T228 | T227 | arg2Of | IL6,against |
R219 | T231 | T229 | arg1Of | confer,"," |
R220 | T222 | T230 | arg1Of | Tocilizumab,could |
R221 | T231 | T230 | arg2Of | confer,could |
R222 | T222 | T231 | arg1Of | Tocilizumab,confer |
R223 | T233 | T231 | arg2Of | benefit,confer |
R224 | T233 | T232 | arg1Of | benefit,clinical |
R225 | T231 | T234 | arg1Of | confer,in |
R226 | T235 | T234 | arg2Of | patients,in |
R227 | T235 | T236 | arg1Of | patients,with |
R228 | T239 | T236 | arg2Of | levels,with |
R229 | T239 | T237 | arg1Of | levels,high |
R230 | T239 | T238 | arg1Of | levels,IL6 |
R231 | T241 | T240 | arg1Of | elements,Essential |
R232 | T241 | T242 | arg1Of | elements,that |
R233 | T247 | T242 | arg2Of | and,that |
R235 | T246 | T243 | arg1Of | entry,process |
R236 | T246 | T244 | arg1Of | entry,SARS-CoV2 |
R237 | T246 | T245 | arg1Of | entry,cell |
R238 | T246 | T247 | arg1Of | entry,and |
R239 | T249 | T247 | arg2Of | characteristics,and |
R240 | T249 | T248 | arg1Of | characteristics,specific |
R241 | T249 | T250 | arg1Of | characteristics,that |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T5 | 30-38 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
T6 | 158-162 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T18 | 148-157 | Disease | denotes | SARS-CoV2 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T19 | 4-115 | Sentence | denotes | Tocilizumab, a monoclonal antibody against IL6, could confer clinical benefit in patients with high IL6 levels. |